创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

王胜峰, 周文虎. 基于仿生DNA酶的肿瘤诊疗研究进展[J]. 药学进展, 2021, 45(5): 363-371.
引用本文: 王胜峰, 周文虎. 基于仿生DNA酶的肿瘤诊疗研究进展[J]. 药学进展, 2021, 45(5): 363-371.
WANG Shengfeng, ZHOU Wenhu. Progress of Research on Biomimetic DNAzyme for Tumor Theranostic Applications[J]. Progress in Pharmaceutical Sciences, 2021, 45(5): 363-371.
Citation: WANG Shengfeng, ZHOU Wenhu. Progress of Research on Biomimetic DNAzyme for Tumor Theranostic Applications[J]. Progress in Pharmaceutical Sciences, 2021, 45(5): 363-371.

基于仿生DNA酶的肿瘤诊疗研究进展

Progress of Research on Biomimetic DNAzyme for Tumor Theranostic Applications

  • 摘要: DNA酶是通过体外筛选获得的具有催化活性的DNA分子,具有稳定性高、特异性好、价格低廉、无免疫原性等优势。其中,具有RNA切割活性的DNA酶具有类似生物体内核酶活性,已在肿瘤诊断和治疗应用领域引起了广泛的关注。通过阐述DNA酶的相关信息,包括其筛选过程、切割RNA的机制以及代表性的DNA酶,进一步介绍DNA酶在RNA干扰、肿瘤多模块治疗、肿瘤联合诊疗以及刺激响应药物递送中的应用,并对DNA酶在本领域内的应用潜力及发展方向进行展望,以期为DNA酶的临床转化提供参考。

     

    Abstract: As a catalytic DNA molecule obtained by in vitro selection, DNAzyme has the advantages of high stability, good specificity, cost-effectiveness and no immunogenicity.Among DNAzymes, the one with RNA-cleavage activity mimics the function of ribozyme in biology, which has attracted particular attention for tumor theranostic applications.This paper describes the basic information of DNAzyme, including its screening process, the mechanism of RNA cleavage and the representative DNAzymes, and introduces the application of DNAzyme in RNA interference, tumor multi-model synergistic therapy, tumor theranostics and stimulus-responsive drug delivery, with a prospect of their potential applications in this field and future development so as to provide reference for the clinical translation of DNAzyme.

     

/

返回文章
返回